塞马格卢提德相关的低度:一系列病例报告
Hani Haytham Mawardi1, Soulafa Adnan Almazrooa1, Siraj Ahmed Dakhil2
1Department of Oral and Diagnostic Sciences, King Abdul-Aziz University - Faculty of Dentistry, Jeddah, Saudi Arabia.
Medicine
|January 11, 2024
概括
在某些患者中,塞马格卢提德 (Ozempic) 的使用可能会导致口腔干燥 (异口症). 这种被称为低水的情况在停止服用药物或接受症状治疗后得到改善.
科学领域:
- 口腔医学是指口腔医学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖和糖尿病是全球性的健康风险.
- 塞马格卢提德 (Ozempic) 越来越多地用于血糖控制和减肥.
- 塞马格卢提德的口服副作用,特别是异口症,没有得到充分的证据.
研究的目的:
- 报告使用塞马格卢提德的患者发生异口症的病例.
- 为了调查塞马格卢提德和低盐度之间的潜在联系.
主要方法:
- 三名超重的女性患者 (BMI 35-37) 使用西马格卢提德减肥,出现了严重的口腔干燥.
- 修改后的施尔默测试表明唾液流量显著减少 (平均9毫升/3分钟).
- 排除了其他导致低盐度的原因.
主要成果:
- 所有患者都经历了严重的口腔干燥和唾液减少.
- 治疗包括药物停用,皮洛卡或保守护理.
- 患者在干预后表现出唾液流的改善.
结论:
- 这是第一个将西马格卢提德使用与二次低盐度 (xerostomia) 联系起来的报告.
- 需要对更大规模的研究进行进一步的研究来证实这些发现.
- 临床医生应该意识到可能的唾液腺功能障碍与semaglutide.
更多相关视频
07:25Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023
2.3K
07:44Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
11.4K
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
